ReviewDie Naturwissenschaften2003
Angiogenesis factors in gliomas: a new key to tumour therapy?
Review in Die Naturwissenschaften, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 47 citations in OpenAlex.
- Testing Hypoxia in Pig Meniscal Culture: Biological Role of the Vascular-Related Factors in the Differentiation and Viability of Neonatal Meniscus.International journal of molecular sciences · 2021Article
- Age-related modulation of angiogenesis-regulating factors in the swine meniscus.Journal of cellular and molecular medicine · 2017Article
- The effect of vascular endothelial growth factor on aggrecan and type II collagen expression in rat articular chondrocytes.Rheumatology international · 2012Article
- Kinase domain insert containing receptor promoter controlled suicide gene system selectively kills human umbilical vein endothelial cells.World journal of gastroenterology · 2006Article
- Angiogenesis in gliomas: biology and molecular pathophysiology.Brain pathology (Zurich, Switzerland) · 2005Review
- Angiogenesis in gliomas: imaging and experimental therapeutics.Brain pathology (Zurich, Switzerland) · 2005Review
- Kinase domain insert containing receptor promotor controlled suicide gene system kills human umbilical vein endothelial cells.World journal of gastroenterology · 2005Article
- The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model.British journal of cancer · 2004Article
- Mechanical overload induces VEGF in cartilage discs via hypoxia-inducible factor.The American journal of pathology · 2004Article
- Functional significance of vascular endothelial growth factor receptor expression on human glioma cells.Journal of neuro-oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis, the formation of new blood vessels, is required for the growth and expansion of tumours. Gliomas, the most common brain tumours, are particularly highly vascularized and, therefore, serve as a model to elucidate the process of tumour angiogenesis and to investigate new anti-angiogenic therapies. This review describes the role of angiogenic factors in glioma angiogenesis and new strategies to inhibit glioma growth by application of anti-angiogenic substances. We focus on vascular endothelial growth factor (VEGF), but also examine the role of angiopoietin and pleiotropic factors such as platelet-derived growth factor (PDGF), pleiotrophin and transforming growth factor-beta (TGF-beta). Strategies to inhibit glioma growth by reducing the action of angiogenic factors, by the application of anti-angiogenic substances such as angiostatin or endostatin, or inactivation of endothelial cells, are discussed. These new anti-angiogenic therapies appear to have a high potential not only for the treatment of gliomas, but also of other tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.